Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study	Platinum-resistant Ovarian Cancer (PROC)	Not yet recruiting	Phase 4	2025-07-20		NCT07075250

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Friendship Hospital	120
Peking University First Hospital	225
Peking University People's Hospital	269
The First Affiliated Hospital of Shanxi Medical University	26
The First Affiliated Hospital of Zhengzhou University	203
Tianchang Yifan Pharmaceutical Co., Ltd.	1
Tianjin People's Hospital	12
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	91

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.